Skip to content
Extreme Investor Network
  • Contact Us
  • Privacy Policy

Spray

FDA Grants Approval for Johnson & Johnson’s Spravato Nasal Spray for Depression Treatment.

January 21, 2025
FDA approves Johnson & Johnson nasal spray Spravato for depression

The Revolutionary Step in Mental Health Treatment: Johnson & Johnson’s Spravato Approved for Standalone Use In a groundbreaking move for the treatment of major depressive disorders, the Food and Drug Administration (FDA) has granted approval … Read more

Categories Business News Tags Approval, depression, FDA, grants, Johnson, Johnsons, Nasal, Spravato, Spray, Treatment

Categories

Recent Posts

  • Market Update – February 6, 2025February 6, 2025
  • Injective (INJ) Hub V2 Unveils New and Improved Features for UsersFebruary 6, 2025
  • Nasdaq 100: Amazon Shares Fall 4% in After-Hours Trading Despite Strong Q4 Earnings ReportFebruary 6, 2025
  • Hilton Worldwide Holdings Inc. (HLT) Stock PredictionsFebruary 6, 2025
  • Dogecoin and Shiba Inu Dip as Meme Coin Market Cap Falls Below $70 Billion – Is This a Chance to Buy?February 6, 2025
  • E.l.f. Beauty (ELF) Q3 2025 Earnings ReportFebruary 6, 2025
  • The Major January Jobs Report Releases This Friday: What to AnticipateFebruary 6, 2025
  • Invest in Stadium Bonds for Solid Tax-Free Income and Exciting OpportunitiesFebruary 6, 2025
  • A Historical Perspective on U.S. Tariff Policies: What Sets Trump ApartFebruary 6, 2025
  • Riot Platforms Reports Surge in Bitcoin Production for January 2025February 6, 2025

Archives

© 2025 Extreme Investor Network

Usermaven | Website analytics and product insights